Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519750 | 0.83 | LMNA (0.61) | LMNACA2CA12CA1CA9 | |
| SCHEMBL10860489 | 0.79 | LMNA (0.55) | LMNACA2CA12CA1CA9 | |
| SCHEMBL9303310 | 0.78 | LMNA (0.50) | LMNACA2CA12CA1CA9 | |
| SCHEMBL8251507 | 0.77 | LMNA (0.53) | LMNACA2CA12CA1CA9 | |
| SCHEMBL24124840 | 0.77 | AGER (0.48) | LMNACA2CA12CA1CA9 | |
| SCHEMBL4569289 | 0.77 | ADAMTS4 (0.53) | LMNACA12CA9ALDH1A1TDP1 | |
| SCHEMBL11307758 | 0.76 | LMNA (0.57) | LMNACA2CA12CA1CA9 | |
| SCHEMBL20930301 | 0.76 | ALDH1A1 (0.49) | LMNACA2CA12CA1CA9 | |
| SCHEMBL30764017 | 0.76 | LMNA (0.61) | LMNACA2CA12CA1CA9 | |
| SCHEMBL2868837 | 0.76 | LMNA (0.61) | LMNACA2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1668020-A2 | NOVEL ADENOSINE A SB 3 /SB RECEPTOR AGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005028489-A2 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | LMNA 3472/4885CA2 1676/4885CA12 4512/4885 |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | LMNA 4265/4885CA2 4239/4885CA12 2291/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | LMNA 4090/4885CA2 3337/4885CA12 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.